

DAFTAR PUSTAKA

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>, accessed on day/month/year.
2. Nicholas Eriksson, G., Chuong B Do, Amy K Kiefer, Joanna L Mountain, David A Hinds, Uta Francke and Joyce Y Tung. Genetic Variants Associated with Breast Size also Influence Breast Cancer Risk. *BMC Medical Genetics*. 2012. 13(53): 1-8.
3. Prasad, M. and R. Sethi. Mutational Analysis of BRCA 2 Gene for SNP Detection Responsible for Breast cancer, *International Journal of Innovative Research in Science. Engineering and Technology*. 2013. 2(11): 6099-6102.
4. Howard M. Stern, H.G., Tomasz Burzykowski, Wafaa Elatre, Carol O'Brien, Mark R. Lackner, Gary A. Pestan, Angela Santiago, Ivonne Villalobos, Wolfgang Eiermann, Tadeusz Pienkowski, Miguel sMartin, Nicholas Robert, John Crown, Paolo Nuciforo, Valerie Bee, John Mackey, Dennis J. Slamon, and Michael F. Press. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. *Clinical cancer research*. 2015. 9(21): 2065-2074.
5. Gholipoor feshkech, R. and S. Arjunan. Genotyping of frequent BRCA1 SNPs in Familial Breast Cancer in Indian Population by Restriction Fragment Length Polymorphism and Sequencing. *Pelagia Research Library*. 2014. 5(2):262-267.
6. Beauclair, S., P. Formento, J. L. Fischel, W. Lescaut, R. Largillier, E. Chamorey, P. Hofman, J. M. Ferrero, G. Page G. Milano, Role of the HER2 [Ile655Val] Genetic Polymorphism in Tumorigenesis and in the Risk of Trastuzumab-related Cardiotoxicity. *Annals of oncology*. 2007. 8(18): 1335-1341.
7. Voet Donald, V Judith G. *Biochemistry*. edisi keempat. John Wiley and Son. Inc: USA. 2008.
8. Nagla R. AbdRaboh, H.H.S. Manal B. Ahmed and Fatehia A. Bayoumi, HER1 R497K and HER2 I655V polymorphism are linked to development of breast cancer. *Disease Markers*. 2013. 43:407-417.
9. Satiroglu-Tufan, N.L., F. Bir, and N. Calli-Demirkan. Investigation of HER-2 codon 655 Single Nucleotide Polymorphism Frequency and c-ErbB-2 Protein Expression Alterations in Gastric Cancer Patients. *World Journal Of Gastroenterology*, 2006, 12(20):3283-3287.
10. Han, X, Diao, L, Xu Y, Xue W, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B. Association Between the HER2 Ile655Val Polymorphism and Response to Trastuzumab in Women With Operable Primary Breast Cancer. *Annals of Oncology*. 2014. 25. 1158-1164.

11. dos Santos A. B., de Araújo, Jéssica Nayara Góes, Bastos, Rafael Caetano, Luchessi, André Ducati, de Rezende, Adriana Augusto, Hirata, Mario Hiroyuki, Hirata, Rosario Dominguez Crespo, Silbiger, Vivian Nogueira: Basic bioinformatics tools for Genotyping Studies. A Practical Exercise with Type 2 Diabetes Mellitus. *International Research Journal of Biochemistry and Bioinformatics*. 2013. 3(6):115-124.
12. National Cancer Institute. What Is Cancer [internet]. 2016. Diambil dari: <https://www.cancer.gov/about-cancer/understanding/what-is-cancer>. 30 September 2016.
13. Cancer Center. What is Cancer [internet]. 2016. Diambil dari: http://www.medicinenet.com/cancer/page2.htm#what_is_cancer. Diakses pada: 30 September 2016
14. Hanahan, Douglas Weinberg, Robert A. Hallmarks of cancer: the next generation. *Journal of cell*. 2011. 144: 646-674.
15. Mendelsohn, John., Howley, Peter., Israel, Mark., Gray, Joe., Thompson, Craig. *The Molecular Basis of Cancer 4th edition*. Saunders.
16. American Cancer Society. Breast Cancer Fact And Figure 2015-2016 [internet]. Atlanta: American Cancer Society. Inc. 2015.
17. Fa, Andrea Mary, Rajana, Anitha, Selvia, R Paula, Solomon FD, A Pilot Study on Screening For 185 Delag Mutation In Breast Cancer Patients in A Tertiary Care Center From South India. *Sri Ramachandra*. 2010, 3: 9-11.
18. Scharl, Anton. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Arbeitsgemeinschaft für gynäkologische Onkologie (AGO) [Internet]. Denmark. 2015. www.ago-online.de
19. Search cancer.org Team. Early Detection, Diagnosis, and Staging Topics. 2016.[ar/breastcancerdiagnosis](http://www.cancer.org/earlydetection). Diakses tanggal 5 Oktober 2016.
20. Breastcancer.Org Team. Breast Cancer Risk factors: Genetics [Internet]. 2016. Diakses dari <http://www.breastcancer.org/risk/factors/genetics>. Pada tanggal 30 September 2016.
21. Zhang W., Yu Y.: The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer. *International Journal of Molecular Sciences* 2011, 12(9): 5672-5683.
22. Luca Braccioli, Marilena V Iorio, Patrizia Casalini. ERBB2 (verbb2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)). *Atlas of Genetics and Cytogenetics in Oncology and Haematology*. 2011. 42.
23. Tao, Yanmei Shen, Chengyong Luo, Shiwen Traoré, Wilfried Marchetto, Sylvie Santoni, Marie-Josée Xu, Linlin Wu, Biao Shi, ChaoMei, Jinghong Luo, Shiwen Traoré, Wilfried Marchetto, Sylvie Santoni, Marie-Josée Xu, Linlin Wu, Biao Shi,

- Chao Mei, Jinghong. Role of Erbin in ErbB2-Dependent Breast Tumor Growth. *Proceedings of the National Academy of Sciences*, 2014. 111(42): E4429-E4438.
- .24. Yeh, Shuyuan Lin, Hui-Kuan Kang, Hong-Yo Thin, Tin Htwe Lin, Ming-Fong Chang, Chawnshang, From Her2/Neu Signal Cascade To Androgen Receptor And Its Coactivators: A Novel Pathway By Induction of Androgen Target Genes Through Map Kinase In Prostate Cancer Cells. *Proceedings of the National Academy of Sciences*, 1999, 96(10): 5458-5463.
25. Seyed Abbas Mirmalek, Maryam Hajilou, Seyed Alireza Salimi Tabatabaee, Yekta Parsa, Soheila Yadollah-Damavandi, and Tina Parsa. Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the PathologicSpecimens of Breast Cancer Patients. *Internasional Journal of Breast Cancer*.2014. 1-3.
26. Stacy L. Moulder, F. Michael Yakes, Senthil K. Muthuswamy, Roberto Bianco, Jean F. Simpson, and Carlos L. Arteaga. Epidermal Growth Factor Receptor (HER1) Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2/neu (erbB2)-overexpressing Breast Cancer Cells in Vitro and in Vivo. *Cancer Reasearch*. 2001. 6: 8887-8895.
27. National Breast Cancer Institute official team. Restriction Fragment Length Polymorphism (RFLP). 2016. <https://www.ncbi.nlm.nih.gov/probe/docs/techrflp/>. Diakses pada tanggal 5 Oktober 2016.
28. Chang, H.-W., et al., SNP-RFLPing 2: an updated and integrated PCR-RFLP tool for SNP genotyping. *BMC bioinformatics*, 2010. 11(1):173.
29. Abd-Elsalam, K.A., Bioinformatic tools and guideline for PCR primer design. *African Journal of biotechnology*. 2003. 2(5):91-95.
30. Jo, U.H., et al., *The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population*. *BMC cancer*, 2008. 8(1):359.

